Document:

Exhibit
10.1

 

DEBT
SATISFACTION AGREEMENT (“AGREEMENT”) ENTERED INTO BY AND BETWEEN ENTEST BIOMEDICAL, INC. (“DEBTOR”) AND
REGEN BIOPHARMA, INC. (“CREDITOR”) DATED MAY 25, 2017.

 

WHEREAS,
As of MAY 25, 2017 , DEBTOR is indebted to CREDITOR in the principal amount of $83,000.

WHEREAS
DEBTOR wishes to accept equity securities of CREDITOR in satisfaction of $83,000 of the total principal debt due to DEBTOR
from CREDITOR (“Settlement Debt”)

 

THEREFORE,
It is agreed as follows:

		1.	STOCK
                                         IN SATISFACTION OF SETTLEMENT DEBT. On or before , May 31 2017 CREDITOR will issue to
                                         DEBTOR 83,000 newly issued shares of the CREDITOR’s Non Voting Convertible Preferred
                                         Stock in full satisfaction of the Settlement Debt.

		2.	ENTIRE
                                         AGREEMENT. This instrument contains the entire agreement of the parties with respect
                                         to the subject matter hereof and supersedes any prior agreements of the parties with
                                         respect to the subject matter hereof. It may be changed only by an agreement in writing
                                         signed by a party against whom enforcement of any waiver, change, modification, extension
                                         or discharge is sought.

		3.	GOVERNING
                                         LAW AND VENUE. Each party hereby irrevocably submits to the exclusive jurisdiction of
                                         the state and federal courts sitting in California for the adjudication of any dispute
                                         hereunder or in connection herewith or with any transaction contemplated hereby or discussed
                                         herein and hereby irrevocably waives, and agrees not to assert in any suit, action or
                                         proceeding, any claim that it is not personally subject to the jurisdiction of any such
                                         court, that such suit, action or proceeding is improper or inconvenient venue for such
                                         proceeding. If either party shall commence an action or proceeding to enforce any provisions
                                         of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
                                         by the other party for its attorneys’ fees and other costs and expenses incurred
                                         with the investigation, preparation and prosecution of such action or proceeding.

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

	Creditor:
    Regen Biopharma, Inc.	Debtor:
    Entest Biomadical, Inc.
	By:
    /s/David Koos	By:/s/
    David Koos
	Its:
    Chairman and CEO	Its:
    Chairman and CEO
	Date:
    May 25, 2017	Date:
    May 25, 2017Exhibit
10.2

 

DEBT
SATISFACTION AGREEMENT (“AGREEMENT”) ENTERED INTO BY AND BETWEEN ENTEST BIOMEDICAL, INC. (“DEBTOR”) AND
BIOTECHNOLOGY PARTNERS BUSINESS TRUST (“CREDITOR”) DATED MAY 25, 2017.

 

WHEREAS,
As of MAY 25, 2017 , DEBTOR is indebted to CREDITOR in the principal amount of $149,000.

WHEREAS
DEBTOR wishes to accept equity securities of CREDITOR in satisfaction of $149,000 of the total principal debt due to DEBTOR
from CREDITOR (“Settlement Debt”)

 

THEREFORE,
It is agreed as follows:

		1.	STOCK
                                         IN SATISFACTION OF SETTLEMENT DEBT. On or before , May 31 2017 CREDITOR will issue to
                                         DEBTOR 149,000 newly issued shares of the CREDITOR’s Non Voting Convertible Preferred
                                         Stock in full satisfaction of the Settlement Debt.

		2.	ENTIRE
                                         AGREEMENT. This instrument contains the entire agreement of the parties with respect
                                         to the subject matter hereof and supersedes any prior agreements of the parties with
                                         respect to the subject matter hereof. It may be changed only by an agreement in writing
                                         signed by a party against whom enforcement of any waiver, change, modification, extension
                                         or discharge is sought.

		3.	GOVERNING
                                         LAW AND VENUE. Each party hereby irrevocably submits to the exclusive jurisdiction of
                                         the state and federal courts sitting in California for the adjudication of any dispute
                                         hereunder or in connection herewith or with any transaction contemplated hereby or discussed
                                         herein and hereby irrevocably waives, and agrees not to assert in any suit, action or
                                         proceeding, any claim that it is not personally subject to the jurisdiction of any such
                                         court, that such suit, action or proceeding is improper or inconvenient venue for such
                                         proceeding. If either party shall commence an action or proceeding to enforce any provisions
                                         of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
                                         by the other party for its attorneys’ fees and other costs and expenses incurred
                                         with the investigation, preparation and prosecution of such action or proceeding.

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

	Creditor:
    Biotechnology Partners Business Trust	Debtor:
    Entest Biomadical, Inc.
	By:
    /s/Timothy G. Foat	By:/s/
    David Koos
	Its:
    Trustee	Its:
    Chairman and CEO
	Date:
    May 25, 2017	Date:
    May 25, 2017Exhibit
10.3

 

DEBT
SATISFACTION AGREEMENT (“AGREEMENT”) ENTERED INTO BY AND BETWEEN ENTEST BIOMEDICAL, INC. (“DEBTOR”) AND
DUNHILL ROSS PARTNERS INC. (“CREDITOR”) DATED MAY 25, 2017.

 

WHEREAS,
As of MAY 25, 2017 , DEBTOR is indebted to CREDITOR in the principal amount of $165,850.

WHEREAS
DEBTOR wishes to accept equity securities of CREDITOR in satisfaction of $165,850 of the total principal debt due to DEBTOR
from CREDITOR (“Settlement Debt”)

 

THEREFORE,
It is agreed as follows:

		1.	STOCK
                                         IN SATISFACTION OF SETTLEMENT DEBT. On or before , May 31 2017 CREDITOR will issue to
                                         DEBTOR 165,850 newly issued shares of the CREDITOR’s Non Voting Convertible Preferred
                                         Stock in full satisfaction of the Settlement Debt.

		2.	ENTIRE
                                         AGREEMENT. This instrument contains the entire agreement of the parties with respect
                                         to the subject matter hereof and supersedes any prior agreements of the parties with
                                         respect to the subject matter hereof. It may be changed only by an agreement in writing
                                         signed by a party against whom enforcement of any waiver, change, modification, extension
                                         or discharge is sought.

		3.	GOVERNING
                                         LAW AND VENUE. Each party hereby irrevocably submits to the exclusive jurisdiction of
                                         the state and federal courts sitting in California for the adjudication of any dispute
                                         hereunder or in connection herewith or with any transaction contemplated hereby or discussed
                                         herein and hereby irrevocably waives, and agrees not to assert in any suit, action or
                                         proceeding, any claim that it is not personally subject to the jurisdiction of any such
                                         court, that such suit, action or proceeding is improper or inconvenient venue for such
                                         proceeding. If either party shall commence an action or proceeding to enforce any provisions
                                         of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
                                         by the other party for its attorneys’ fees and other costs and expenses incurred
                                         with the investigation, preparation and prosecution of such action or proceeding.

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

	Creditor:
    Dunhill Ross Partners Inc.	Debtor:
    Entest Biomadical, Inc.
	By:
    /s/Timothy G. Foat	By:/s/
    David Koos
	Its:
    President	Its:
    Chairman and CEO
	Date:
    May 25, 2017	Date:
    May 25, 2017Exhibit
10.4

 

DEBT
SATISFACTION AGREEMENT (“AGREEMENT”) ENTERED INTO BY AND BETWEEN ENTEST BIOMEDICAL, INC. (“DEBTOR”) AND
BOSTONIA PARTNERS INC. (“CREDITOR”) DATED MAY 25, 2017.

 

WHEREAS,
As of MAY 25, 2017 , DEBTOR is indebted to CREDITOR in the principal amount of $327,681.

WHEREAS
DEBTOR wishes to accept equity securities of CREDITOR in satisfaction of $327,681 of the total principal debt due to DEBTOR
from CREDITOR (“Settlement Debt”)

 

THEREFORE,
It is agreed as follows:

		1.	STOCK
                                         IN SATISFACTION OF SETTLEMENT DEBT. On or before , May 31 2017 CREDITOR will issue to
                                         DEBTOR 327,681 newly issued shares of the CREDITOR’s Non Voting Convertible Preferred
                                         Stock in full satisfaction of the Settlement Debt.

		2.	ENTIRE
                                         AGREEMENT. This instrument contains the entire agreement of the parties with respect
                                         to the subject matter hereof and supersedes any prior agreements of the parties with
                                         respect to the subject matter hereof. It may be changed only by an agreement in writing
                                         signed by a party against whom enforcement of any waiver, change, modification, extension
                                         or discharge is sought.

		3.	GOVERNING
                                         LAW AND VENUE. Each party hereby irrevocably submits to the exclusive jurisdiction of
                                         the state and federal courts sitting in California for the adjudication of any dispute
                                         hereunder or in connection herewith or with any transaction contemplated hereby or discussed
                                         herein and hereby irrevocably waives, and agrees not to assert in any suit, action or
                                         proceeding, any claim that it is not personally subject to the jurisdiction of any such
                                         court, that such suit, action or proceeding is improper or inconvenient venue for such
                                         proceeding. If either party shall commence an action or proceeding to enforce any provisions
                                         of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed
                                         by the other party for its attorneys’ fees and other costs and expenses incurred
                                         with the investigation, preparation and prosecution of such action or proceeding.

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

	Creditor:
    Bostonia Partners Inc.	Debtor:
    Entest Biomadical, Inc.
	By:
    /s/Timothy G. Foat	By:/s/
    David Koos
	Its:
    President	Its:
    Chairman and CEO
	Date:
    May 25, 2017	Date:
    May 25, 2017

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]